Article

A legacy made from lemonade

Author(s):

Bunmi Ishola

Ten years ago lemonade began making a difference in the life of childhood cancer patients across the U.S. At 4 years old, a little girl understood that in order to find a cure for childhood cancers, research was needed. And to do research, you needed money.So Alex Scott made lemonade, and began "fighting childhood cancer, one cup at a time." Between that first stand in 2000, and the ones she held each year until 2004, when she died, Alex raised over $1 million. And her parents, Jay and Liz Scott, formed the Alex's Lemonade Stand Foundation, allowing her legacy to be continued.This Saturday, June 12, marks the 10-year anniversary of Alex's original lemonade stand. Her parents, Jay and Liz Scott, are hosting a day of remembrance for their daughter and the hope she inspired. The event takes place at Alex's elementary school, Penn Wynne, in Wynnewood, Pennsylvania.For more information about the event, click here.

Related Videos
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Image of Dr. Christopher R. Flowers.
a man and a woman in front of a dark blue background
a man and a woman in front of a dark blue background
a man and a woman in separate boxes in front of a dark blue background
Image of woman with black hair.
Related Content
Researchers have found an association between the use of ICIs for cancer treatment and a risk of new onset psoriasis: © Dragana Gordic - stock.adobe.com
March 3rd 2025

Immune Checkpoint Inhibitors For Cancer Associated With Psoriasis Risk

Alex Biese
Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Illustration of blood cells.
March 3rd 2025

Rusfertide Elicits Promising Responses in Polycythemia Vera

Alex Biese
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of doctor and man.
March 3rd 2025

My Journey With Squamous Cell Carcinoma

John H. Clark III
A patient shares his experience with a squamous cell carcinoma diagnosis, treatment and recovery.
Illustration of lungs.
March 2nd 2025

First Patient With Small Cell Lung Cancer Dosed With Peluntamig

Spencer Feldman
The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.